Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532764 | 0.88 | ALDH1A1 (0.53) | ALDH1A1HIF1ASLC6A4TDP1TSHR | |
| SCHEMBL9416708 | 0.83 | GPR35 (0.51) | ALDH1A1TDP1TSHRCYP1A2KMT2A | |
| SCHEMBL17083672 | 0.82 | ALDH1A1 (0.53) | ALDH1A1HIF1ATDP1TSHRCYP1A2 | |
| SCHEMBL2174996 | 0.81 | ALDH1A1 (0.56) | ALDH1A1TDP1TSHRCYP1A2KMT2A | |
| SCHEMBL30643106 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TDP1TSHRCYP1A2CHRNB2 | |
| SCHEMBL12431422 | 0.80 | HSD17B10 (0.55) | ALDH1A1SLC6A4TDP1TSHRCYP1A2 | |
| SCHEMBL27077028 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRCYP1A2KMT2A | |
| SCHEMBL2173166 | 0.79 | ALDH1A1 (0.58) | ALDH1A1TDP1TSHRCYP1A2CHRNB2 | |
| SCHEMBL16207595 | 0.79 | ALDH1A1 (0.53) | ALDH1A1HIF1ATDP1TSHRCYP1A2 | |
| SCHEMBL19182321 | 0.78 | CYP1A2 (0.47) | ALDH1A1HIF1ACYP1A2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4349820-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-3658539-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-12-28 | — | — | US | disclosed |
| CN-117209447-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117143042-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-111094243-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-11203579-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2021-12-21 | — | — | US | disclosed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| US-20210171477-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2021-06-10 | — | — | US | disclosed |
| EP-3658539-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis Inflammasome Research, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
| WO-2019023147-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203579-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP3, NLRP1, IAPP | ALDH1A1 3482/4885HIF1A 3938/4885SLC6A4 2808/4885 |
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 1972/4885HIF1A 2689/4885SLC6A4 2344/4885 |
| US-20210171477-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP3, NLRP1, IAPP | ALDH1A1 3482/4885HIF1A 3938/4885SLC6A4 2808/4885 |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | ALDH1A1 1972/4885HIF1A 2689/4885SLC6A4 2344/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | ALDH1A1 1972/4885HIF1A 2689/4885SLC6A4 2344/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | ALDH1A1 1972/4885HIF1A 2689/4885SLC6A4 2344/4885 |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 1972/4885HIF1A 2689/4885SLC6A4 2344/4885 |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | ALDH1A1 165/4885HIF1A 4474/4885SLC6A4 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.